Simon Barry J. sold $165K of IBRX
Simon Barry J. sold 23,033 shares of ImmunityBio, Inc. (IBRX) at $7.18 ($0.17M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates insider activity records and may slightly influence sentiment, but it does not introduce a new operational/clinical/regulatory catalyst for IBRX.
Market read
Traders may monitor for patterns in future insider transactions, but this specific event is typically lower-signal due to 10b5-1 pre-arrangement.
What to watch
The filing doesn’t clarify whether the director’s remaining holdings changed materially beyond the disclosed post-transaction balance, nor does it indicate future planned sales cadence.
Background
This is an SEC Form 4 insider transaction for ImmunityBio, Inc., reported as an open-market sale by a director under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Director Simon Barry sold 23,033 ImmunityBio shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any effect is more about sentiment/positioning than fundamentals.
The filing provides a concrete datapoint (sale size/price) but not a new company-specific catalyst; 10b5-1 reduces interpretive weight.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide development.
None indicated.
None indicated.
Counterpoint
10b5-1 sales can be routine and may not reflect bearish expectations; traders may fade any knee-jerk negative read-through.
Key entities
- issuerImmunityBio, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderSimon Barry J.
Director who executed the open-market sale under a 10b5-1 plan.
